In order to grab a share of China's huge potential medical devices business, multinational medical device manufacturers are establishing foothold in the medium- and low-end market through collaborations or mergers. In the patient monitoring sector, market share of MNCs has declined from a high of 70 percent to the current 30 percent due to lower-priced local brands such as Shenzhen Mindray and Goldway. To consolidate its leading position in China, Philips recently made its first acquisition by buying Goldway Industrial. Industry analysts observe that the acquisition will heat up the competition if Philips puts its brand on Goldway-made products without raising prices. To address the possible adverse impact, Mindray has begun shifting its focus to the high-end market to build up its international competitive advantage. (Click here for more - Chinese Language)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
Recent moves in the industry include changes at the top at Mitsubishi Tanabe Pharma and MC2 Therapeutics, plus MindMed acquires chief financial officer from Longboard Pharma.
In a turn of fortunes, Lyra Therapeutics has reported positive Phase III results for LYR-210 in chronic rhinosinusitis, boosting hopes for US approval. The company plans to submit an NDA and pursue further trials, but its cash position is precarious.
IGI CEO tells Scrip about the “very encouraging” feedback at ASCO to promising early data for the firm's first-in-class investigational trispecific antibody in multiple myeloma. Is a licensing deal in the offing?